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Antiphospholipid Syndrome and
Recurrent Thrombotic Valve Disease
Dawn C. Scantlebury, MBBS, Vuyisile T. Nkomo, MD, MPH, Maurice Enriquez-Sarano, MD
Rochester, Minnesota28-year-old woman with a history of preeclampsia presented with symptomatic severeAmitral regurgitation. Echocardiography revealed sessile thickening along the edges ofboth mitral leaﬂets (A, B, Online Video 1) suspicious for nonbacterial thrombotic
endocarditis. She underwent mitral valve replacement with a bioprosthesis due to a wish for further
childbearing. Gross appearance (C) and pathology conﬁrmed nonbacterial thrombotic endo-
carditis, and positive serology conﬁrmed antiphospholipid syndrome.
Post-operatively, the patient complied poorly with anticoagulation and 4 months later
presented with recurrent dyspnea, restricted valve opening, bioprosthetic leaﬂet thrombi (D,
Online Video 2), and 20-mm Hg transvalvular mitral gradient. Anticoagulation was reinitiated,
with rapid symptomatic improvement, mitigating a need for re-operation. Later imaging (E)
demonstrated resolution of the thrombi.
Antiphospholipid syndrome is a multisystem thrombotic disorder (1) causing preeclampsia and
valvular thrombosis on both native and prosthetic valves, including bioprostheses, as demonstrated.
Life-long anticoagulation is indicated. Bioprosthesis thrombosis resolution can be achieved by
sustained anticoagulation without re-operation.
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